These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1971905)

  • 21. Testing blood donors for HTLV-II.
    Bianco C; Tegtmeier G
    Lancet; 1993 Jun; 341(8858):1477. PubMed ID: 8099170
    [No Abstract]   [Full Text] [Related]  

  • 22. Human T-cell lymphotrophic virus antibody in phakic cystoid macular edema.
    Maturi RK; Folk JC
    Arch Ophthalmol; 1999 Nov; 117(11):1571. PubMed ID: 10565535
    [No Abstract]   [Full Text] [Related]  

  • 23. HTLV infection in a group of prostitutes and their male sexual clients in Brazil: seroprevalence and risk factors.
    Bellei NC; Granato CF; Tomyiama H; Castelo A; Ferreira O
    Trans R Soc Trop Med Hyg; 1996; 90(2):122-5. PubMed ID: 8761567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Investigation of anti-HTLV I/II seroprevalence in healthy blood donors in Izmir region, Turkey].
    Sertöz R; Turhan A; Bozkurt H; Samlıoğlu P; Değirmenci A; Aydınok Y; Erensoy S
    Mikrobiyol Bul; 2010 Oct; 44(4):579-84. PubMed ID: 21063970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of HIV infections among patients attending a Parisian anonymous testing center between 1988 and 1993.
    Mazeron MC; Cervoni J; Alain S; Honderlick P; Raskine L; Chassany O; Caulin C; Sanson-Le Pors MJ
    Pathol Biol (Paris); 1994 May; 42(5):530-2. PubMed ID: 7824327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seroprevalence of HTLV-1 and HTLV-2 among intravenous drug users and persons in clinics for sexually transmitted diseases.
    Khabbaz RF; Onorato IM; Cannon RO; Hartley TM; Roberts B; Hosein B; Kaplan JE
    N Engl J Med; 1992 Feb; 326(6):375-80. PubMed ID: 1729620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users.
    Page JB; Lai SH; Chitwood DD; Klimas NG; Smith PC; Fletcher MA
    Lancet; 1990 Jun; 335(8703):1439-41. PubMed ID: 1972217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HTLV-I/II antibodies in UK blood donors.
    Salker R; Tosswill JH; Barbara JA; Runganga J; Contreras M; Tedder RS; Parra-Mejia N; Mortimer PP
    Lancet; 1990 Aug; 336(8710):317. PubMed ID: 1974006
    [No Abstract]   [Full Text] [Related]  

  • 29. Seroepidemiology and clinical aspects of human T-cell lymphotropic virus type I/II infection in a cohort of intravenous drug users in New York City.
    Brown LS; Chu A; Allain JP; Lee H; Cerney M; Nemoto T
    N Y State J Med; 1991 Mar; 91(3):93-7. PubMed ID: 2047026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibodies to HTLV-I among blood donors in Latvia, USSR.
    Murovska M; Taguchi H; Iwahara Y; Sawada T; Kukaine R; Miyoshi I
    Int J Cancer; 1991 Jan; 47(1):158-9. PubMed ID: 1985873
    [No Abstract]   [Full Text] [Related]  

  • 31. HTLV-I infections in French Guiana as monitored by western-blot, dot-blot and PCR techniques.
    Moynet D; Berteau F; Astier-Gin T; Legrand E; Sainte-Foie S; Joly F; Moreau JP; Guillemain B
    Leukemia; 1992; 6 Suppl 3():106S-109S. PubMed ID: 1602804
    [No Abstract]   [Full Text] [Related]  

  • 32. [Screening of donor blood for viral markers. Anti-HIV, HBsAg and anti-HTLV-I/II in Denmark 1990-1999].
    Dickmeiss E; Christiansen AH; Smith E
    Ugeskr Laeger; 2001 May; 163(19):2623-8. PubMed ID: 11360355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Retrospective blood transfusion survey from blood donor with anti-HTLV-I/II antibodies].
    Branger M; Elias A; Coste J; Jaulin P
    Presse Med; 1991 Apr; 20(16):771. PubMed ID: 1828597
    [No Abstract]   [Full Text] [Related]  

  • 34. Serologic discrimination of human T cell lymphotropic virus infection by using a synthetic peptide-based enzyme immunoassay.
    Lal RB; Rudolph DL; Lairmore MD; Khabbaz RF; Garfield M; Coligan JE; Folks TM
    J Infect Dis; 1991 Jan; 163(1):41-6. PubMed ID: 1984475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of human T-lymphotropic virus type-I and type-II testing in donors and patients.
    Fischer HE; Lichtiger B; Glassman AB
    Ann Clin Lab Sci; 1995; 25(5):373-80. PubMed ID: 7486811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seroprevalence of Human T-Cell Lymphotropic Virus-1/2 in Blood Donors in Northern Pakistan: Implications for Blood Donor Screening.
    Niazi SK; Bhatti FA; Salamat N
    J Coll Physicians Surg Pak; 2015 Dec; 25(12):874-7. PubMed ID: 26691361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human T lymphotropic virus types I and II proviral sequences in Argentinian blood donors with indeterminate Western blot patterns.
    Mangano AM; Remesar M; del Pozo A; Sen L
    J Med Virol; 2004 Oct; 74(2):323-7. PubMed ID: 15332282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High prevalence of HTLV-I and HTLV-II among blood donors in Argentina: a South American health concern.
    Biglione MM; Astarloa L; Salomón HE;
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):1-4. PubMed ID: 15665638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [HTLV-I antibody screening of blood donors].
    Schwarzfischer G; Schätzl H; Bäcker U; Weise W; von der Helm K; Deinhardt F
    Beitr Infusionsther; 1991; 28():29-31. PubMed ID: 1725641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [HTLV-I/II seroprevalence and risk factors associated with infection in a blood donor population in Córdoba, Argentina].
    Gallego S; Maturano E; Recalde A; Gastaldello R; Sileoni S; Bepre H; Medeot S
    Rev Argent Microbiol; 2001; 33(3):182-6. PubMed ID: 11594010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.